FindTrial
Sign In

Atezolizumab and Recombinant Human Hyaluronidase

BIOLOGICAL2 trials

Sponsors

University of Southern California, National Cancer Institute (NCI)

Conditions

Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8

Phase 2

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer
Active, not recruitingNCT05340309
University of Southern CaliforniaLung Non-Small Cell Carcinoma, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8 +8
Start: 2022-12-07End: 2027-12-31Updated: 2026-01-29

Phase 3

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
RecruitingNCT07388524
National Cancer Institute (NCI)Lung Non-Small Cell Carcinoma
Start: 2027-03-02End: 2032-09-30Target: 336Updated: 2026-09-18

Related Papers

Breaking barriers for cancer clinical trials: A multi-tiered interventional approach to boost racial and ethnic minority participation in early-phase studies.
Journal of Clinical Oncology2024-06-01